TransGen Biotech Concludes a Successful Showcase at Medlab Middle East 2025, Joining Hands with Global Healthcare Leaders
From February 5 to 8, 2025, leading companies and experts from the global healthcare industry gathered at the Dubai World Trade Centre for the annual Medlab Middle East 2025. As the largest laboratory and medical trade show in the Middle East, this year’s event brought together 747 exhibitors and welcomed over 30,000 visitors from across the world. The exhibition floor buzzed with activity as industry leaders and experts exchanged insights, explored cutting-edge technologies, and discussed the future of the global healthcare market.
As a longstanding exhibitor at Medlab Middle East, TransGen Biotech made a strong start to the year by presenting a diverse portfolio of innovative products and technologies. Our booth quickly became a focal point for professional visitors, who showed strong interest in our key offerings, including:
★ NGS Workflow Solutions
★ Core Enzymes for Molecular Diagnostics
★ Automated Nucleic Acid Extraction Systems
★ Host Cell Residual DNA Detection Kits
★ Cell Culture & Analysis Products
★ Laboratory Instruments & Consumables
★ Serum-free Media for T Cells and NK Cells
Throughout the event, TransGen Biotech engaged in productive conversations with visitors from over 30 countries, including the UAE, Italy, Iran, Kuwait, India, Pakistan, South Korea, Saudi Arabia, Sri Lanka, Mali, Jordan, Algeria, Russia, Poland, the UK, Germany, Bangladesh, Uzbekistan, and Serbia, among others. We successfully established initial cooperation intentions with many potential partners, further strengthening our presence in both the Middle Eastern and global markets.
Committed to Advancing Global Diagnostics — Driven by Science, Dedicated to Industry
At TransGen Biotech, we are firmly committed to the philosophy of “Driven by Science, Dedicated to Industry.” While ensuring consistent product quality and reliability, we continuously enhance our customer service and user experience, earning wide recognition from both research and industrial customers worldwide. Looking ahead, we will continue to invest in technological innovation and product development, working hand in hand with our global partners to drive sustainable growth in the field of in vitro diagnostics.
